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The role of dual specificity phosphatase 1 (DUSP1) in inducible nitric oxide synthase (iNOS) expression in A549 human
pulmonary epithelial cells, J774 mouse macrophages and primary mouse bone marrow-derived macrophages (BMMs) was
investigated. iNOS expression was induced by a cytokine mixture (TNF, IFNγ and IL-1β) in A549 cells and by LPS in J774 cells,
and it was inhibited by p38 MAPK inhibitors SB202190 and BIRB 796. Stimulation with cytokine mixture or LPS enhanced also
DUSP1 expression. Down-regulation of DUSP1 by siRNA increased p38 MAPK phosphorylation and iNOS expression in A549
and J774 cells. In addition, LPS-induced iNOS expression was enhanced in BMMs from DUSP1(−/−) mice as compared to that in
BMMs fromwild-typemice. The results indicate that DUSP1 suppresses iNOS expression by limiting p38MAPK activity in human
and mouse cells. Compounds that enhance DUSP1 expression or modulate its function may be beneficial in diseases complicated
with increased iNOS-mediated NO production.
1. Introduction
Nitric oxide (NO) is a gaseous signaling molecule that regu-
lates various physiological and pathophysiological processes
in many tissues and organ systems. NO is synthesized from
L-arginine in a reaction catalyzed by nitric oxide synthase
(NOS) enzyme. Three NOS enzyme isoforms exist: neuronal
NOS (nNOS), inducible NOS (iNOS), and endothelial NOS
(eNOS). nNOS and eNOS are constitutively expressed, and,
in general, they produce relatively small amounts of NO
in the context of physiological regulation of cellular and
tissue functions. The expression of iNOS is induced by a
number inflammatory and other stimuli, such as inflamma-
tory cytokines, bacterial products, and hypoxia. NO is an
important eﬀector molecule in microbicidal host defense,
and it serves as a regulatory and proinflammatory molecule
in acute and chronic inflammatory responses [1–4].
The expression of iNOS is regulated at transcriptional
and posttranscriptional levels. There are considerable diﬀere-
nces in the transcriptional regulation of mouse and human
iNOS expression. Mouse iNOS promoter activity is sub-
stantially induced by interferon (IFN)γ and bacteria-derived
substances, such as lipopolysaccharide (LPS). iNOS pro-
moter contains two regions responsive to LPS and IFNs.
The proximal region is located between −48 and −209 bp
upstream of transcriptional start site and contains binding
site for nuclear factor κB (NK-κB) and is essential for
NF-κB-dependent inducible iNOS promoter activity. The
distal region, at position −913 to −1029 bp, contains NF-
kB binding site, gamma-activated site (GAS) and two
copies of interferon-stimulated response element (ISRE) [5].
Interferon-stimulated gene factor 3 (ISGF3; a heterotrimer
of signal transducer and activator of transcription (STAT)1,
STAT2, and interferon regulatory factor (IRF)9) bound to the
distal responsive element and NF-κB bound to the proximal
responsive element have been shown to cooperate to induce
iNOS expression [6]. Several other transcription factors have
been shown to regulate mouse iNOS transcription including
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IRF-1, Octamer factor (Oct-1), activating protein-1 (AP-1),
and high-mobility group protein HMG-I(Y) [2, 7].
Transcriptional regulation of human iNOS expression
shows complexity. Human iNOS promoter shows basal
promoter activity, and regulatory elements involved in the
cytokine-induced human iNOS transcription are located
between −3.8 and −16 kb upstream of the transcriptional
start site [7, 8]. A number of transcription factors con-
tribute to human iNOS transcription. NF-κB and STAT1
are considered to be the key transcription factors regulating
human iNOS transcription [9, 10]. AP-1 has been reported to
have positive and negative eﬀects on human iNOS promoter
activity [11, 12]. Several other transcription factors have
been shown to be involved in human iNOS transcription
including Oct-1, cAMP-responsive element-binding protein,
CCAAT-enhancer box-binding protein, STAT3, NF-IL6, and
hypoxia-induced factor-1 [7].
Mitogen-activated protein kinases (MAPKs) have been
shown to regulate iNOS expression, especially by posttransc-
riptional mechanisms. iNOSmRNA stability has been shown
to be regulated by p38 MAPK and Jun N-terminal kinase
(JNK) [13–15]. Other factors involved in the regulation of
iNOS expression at posttranscriptional level include trans-
forming growth factor β, glucocorticoids, and inhibitors of
calcineurin [16–18]. Proteins that bind to the 3′ untranslated
region of iNOS mRNA and regulate iNOS expression at
posttranscriptional level include embryonic lethal abnor-
mal visual RNA-binding protein HuR, tristetraprolin, KH-
type splicing regulatory protein, and heterogeneous nuclear
ribonucleoprotein D and I [13, 19–22].
MAPKs are a group of serine/threonine protein kinases
involved in the cellular signal transduction, and the members
of this signalling pathway group include p38 MAPK, JNK
and p42/44 ERK. They are activated via phosphorylation
of specific tyrosine and threonine residues by the upstream
kinases. MAPKs regulate various physiological processes,
including cell growth, diﬀerentiation, and stress responses,
and p38 and JNK are associated with the regulation of
inflammatory and immune responses [23–25]. There are
four p38 MAPK isoforms (p38α, p38β, p38γ, and p38δ),
all encoded by separate genes. Especially p38α and p38β
have been found to regulate immune response [24–26].
Many diﬀerent stimuli, including LPS, cytokines and growth
factors, activate p38 MAPK pathway [27–31]. The activation
of p38 MAPK is involved in the expression of several
inflammatory genes, such as tumor necrosis factor (TNF),
interleukin(IL)-1, IL-6, IL-8, cyclooxygenase-2 (COX-2) and
iNOS [13, 26, 27, 32–35]. p38 MAPK inhibitors have
been shown to suppress the expression of inflammatory
cytokines, progression of arthritis, and pulmonary fibrosis in
animal models and attenuate inflammatory response during
endotoxemia in humans [36–38].
Dual specificity phosphatases (DUSPs) are a group of
protein phosphatases that dephosphorylate phosphotyrosine
and phosphoserine/threonine residues in their target pro-
teins and regulate several intracellular signaling pathways.
DUSPs associated with MAPK pathways (at least ten mem-
bers) diﬀer from each other by substrate specificity, tissue
distribution, cellular localization, and expressional pattern
[39, 40]. DUSP1 dephosphorylates tyrosine and threonine
residues in MAPK Thr-Xaa-Tyr activation motif and thereby
inactivates MAPK. DUSP1 has substrate specificity towards
p38 and JNK over ERK [41–44]. DUSP1 deficient mice
produce elevated levels of inflammatory cytokines and
developmore severe NO-mediated hypotensive response and
organ failure after administration of LPS or peptidoglycan
and lipoteichoic acid [41, 43, 45, 46].
We have previously reported that DUSP1 negatively reg-
ulates IL-6, IL-8 and COX-2 expression in A549 human epit-
helial cells [47]. In addition, we have recently shown that
the suppression of the expression of COX-2, matrix metal-
loproteinase 3 (MMP-3), and IL-6 by antirheumatic drug
aurothiomalate in mouse and human chondrocytes and
cartilage is mediated by DUSP1 [48]. In the present study,
we investigated the eﬀect of DUSP1 on the expression of
iNOS in human and murine cells. The main finding was
that DUSP1 suppresses iNOS expression by limiting p38
signaling in human cells, which is a novel finding, and this
was observed in mouse macrophages also.
2. Materials and Methods
2.1. Materials. Reagents were obtained as follows. BIRB 796
(1-(5-tertbutyl-2-p-tolyl-2H-pyrazol-3-yl)-3(4-(2-morpho-
lin-4-yl-ethoxy)naphthalen-1-yl)urea, Axon MedChem, Gr-
oningen, The Netherlands), SB202190 (4-[4-(4-Fluorophe-
nyl)-5-(4-pyridinyl)-1H-imidazol-2-yl] phenol, Tocris Bios-
cience, Bristol, UK), recombinant human TNF, recombinant
human IFNγ, recombinant human IL-1β, recombinantmou-
se macrophage colony-stimulating factor (M-CSF) (R&D
Systems Inc., Minneapolis, Mass, USA), medetomidine (Do-
mitor 1mg/mL, Orion Oyj, Espoo, Finland), and ketamine
(Ketalar 10mg/mL, Pfizer Oy Animal Health, Helsinki, Fin-
land) were obtained as indicated. All other reagents were
purchased from Sigma Chemicals Co. (Saint Louis, Mo,
USA) unless otherwise stated below.
2.2. Cell Culture. A549 human lung epithelial cells (ATCC,
Manassas, Va, USA) were cultured at 37◦C in 5% CO2
atmosphere in Ham’s F12K (Kaighn’s modification) medium
supplemented with 5% heat-inactivated fetal bovine serum
(FBS), 100U/mL penicillin, 100 μg/mL streptomycin, and
250 ng/mL amphotericin B (all from Invitrogen, Paisley,
UK). J774 macrophages (ATCC, Manassas, Va, USA) were
cultured at 37◦C in 5% CO2 atmosphere in Dulbecco’s
modified Eagle’s medium with Ultraglutamine 1 (Lonza,
Verviers Sprl, Verviers, Belgium) supplemented with 5%
heat-inactivated FBS, 100U/ml penicillin, 100 μg/mL strep-
tomycin, and 250 ng/mL amphotericin B.
For experiments, A549 cells (4 × 105 cells/well) were
seeded on a 24-well plate and grown for 48 h prior to the
experiments. J774 cells (2 × 105 cells/well) were seeded on a
24-well plate and grown for 72 h prior to the experiments.
BIRB 796 and SB202190 were dissolved in DMSO. BIRB 796,
SB202190 at concentrations indicated, or DMSO (v/v 0.1%)
were added to the cells in fresh culture medium containing
5% FBS and antibiotics 30 min prior to the stimulation
with a cytokine mixture containing TNF, IFNγ, and IL-1β
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(10 ng/mL each) or LPS (10 ng/mL). Cells were further
incubated for the time indicated.
2.3. Animals and Isolation and Culture of Bone Marrow
Macrophages. Murine bone marrow macrophages (BMMs)
were obtained from wild-type and DUSP1(−/−) C57BL/6
mice. Inbred C57BL/6 DUSP1(−/−) mice were originally
generated by the R. Bravo laboratory at Bristol-Myers
Squibb Pharmaceutical Research Institute [49], and the
wild-type mice originated from the same strain. The study
was approved by the Animal Care and Use Committee of
the University of Tampere and the respective provincial
committee for animal experiments. Female mice aged 10–12
weeks were used in the study. The mice were anesthetized
by intraperitoneal injection of 0.05mg/100 g body weight of
medetomidine and 7.5mg/100 g body weight of ketamine.
Finally, mice were euthanized by cervical dislocation. Bone
marrow cells were obtained by aspiration with sterile syringe
needle from femur and fibia. BMMs were generated from
bonemarrow cells with 5–7 days of incubation in RPMI 1640
medium supplemented with 10% heat-inactivated fetal calf
serum (FCS), 100U/mL penicillin, 100 μg/mL streptomycin
and 10 ng/mL M-CSF. BMMs (1 × 106 cells/well) were then
seeded on a 24-well plate and cultured overnight in complete
culture medium. BMMs were then serum-starved overnight.
In the beginning of the experiment, LPS was added to the
cells along with the culture medium containing 10% FCS
and antibiotics, and BMMs were incubated for the time
indicated.
2.4. Preparation of Cell Lysates for Western Blot Analysis. At
the indicated time points, culture medium was removed.
Cells were rapidly washed with ice cold PBS and solu-
bilized in cold lysis buﬀer containing 10mM Tris-HCl,
5mM EDTA, 50mM NaCl, 1% Triton-X-100, 0.5 mM
phenylmethylsulfonyl fluoride, 1mM sodiumorthovanadate,
20 μg/mL leupeptin, 50 μg/mL aprotinin, 5mM sodium
fluoride, 2mM sodium pyrophosphate, and 10 μM n-octyl-
D-glucopyranoside. After incubation for 20min on ice,
lysates were centrifuged (12 000 g, 10min) and supernatants
were collected, mixed in a ratio of 1 : 4 with SDS loading
buﬀer (62.5mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS,
0,025% bromophenol blue, and 5% mercaptoethanol) and
stored at−20◦C until analyzed. Protein concentrations in the
samples were measured by the Coomassie blue method.
2.5. Western Blotting. Actin (sc-1616-R), DUSP1 (M-18, sc-
1102), lamin A/C (sc-20681), and polyclonal antirabbit (sc-
2004) and polyclonal antigoat (sc-2020) antibodies were
obtained from Santa Cruz Biotechnology (Santa Cruz, Calif,
USA). Phospho-p38 MAPK (Cat. no. 9218), p38 MAPK
(Cat. no. 9212), mitogen-activated protein kinase-activated
protein kinase 2 (MK2) (Cat. no. 3042) and phospho-MK2
(27B7, Cat. no. 3007) antibodies (Cell Signaling Technology
Inc, Beverly, Mass, USA) were obtained as indicated. Prior
to Western blot analysis, the protein samples were boiled
for 10 min. Equal aliquots of protein (10–20 μg) were
loaded on a 10% SDS-polyacrylamide electrophoresis gel and
separated by electrophoresis. Proteins were transferred to
Hybond enhanced chemiluminescence nitrocellulose mem-
brane (Amersham, Buckinghamshire, UK) by semidry elec-
troblotting. After transfer, the membrane was blocked in
TBS/T (20mM Tris-base pH 7.6, 150mM NaCl, and 0.1%
Tween-20) containing 5% nonfat milk for 1 h at room
temperature. For detection of phospho-proteins, membranes
were blocked in TBS/T containing 5% bovine serum albu-
min. Membranes were incubated overnight at 4◦C with the
primary antibody and for 1 h with the secondary antibody
in room temperature, and the chemiluminescent signal was
detected by ImageQuant LAS 4000mini (GE Healthcare Bio-
Sciences AB, Uppsala, Sweden). The chemiluminescent sig-
nal was quantified with ImageQuant TL 7.0 Image Analysis
Software.
2.6. NO Measurement. Cells were incubated with com-
pounds of interest for 24 h. Culture medium was then
collected, and nitrite (a stable metabolite of NO in aqueous
conditions) levels were measured by the Griess reaction.
2.7. RNA Extraction and Quantitative RT-PCR. Primers
and probes for quantitative RT-PCR were obtained from
Metabion International AG (Martinsried, Germany). At
the indicated time points, culture medium was removed
and total RNA extraction was carried out with GenElute
Mammalian Total RNA Miniprep Kit (Sigma-Aldrich, St
Louis, Mo, USA) according to the manufacturer’s instruc-
tions. Total RNA was reverse-transcribed to cDNA using
TaqMan Reverse Transcription reagents and random hex-
amers (Applied Biosystems, Foster City, Calif, USA). cDNA
obtained from the RT-reaction was diluted 1: 20 with
RNAse-free water and was subjected to quantitative PCR
using TaqMan Universal PCR Master Mix and ABI PRISM
7000 Sequence detection system (Applied Biosystems, Foster
City, Calif, USA). The primer and probe sequences and
concentrations (Table 1) were optimized according to manu-
facturer’s guidelines in TaqMan Universal PCR Master Mix
Protocol part number 4304449 revision C. Expression of
human Lamin A/C mRNA and human DUSP1 mRNA were
measured using TagMan Gene Expression Assays (Applied
Biosystems, Foster City, Calif, USA). PCR reaction parame-
ters were as follows: incubation at 50◦C for 2min, incubation
at 95◦C for 10min, and thereafter 40 cycles of denaturation
at 95◦C for 15 s and annealing and extension at 60◦C for
1min. Each sample was determined in duplicate. A standard
curve method was used to determine the relative mRNA
levels as described in the Applied Biosystems User Bulletin:
A standard curve for each gene was created using RNA
isolated from A549 cells stimulated with cytokines (TNF, IL-
1β, and IFNγ; 10 ng/mL each) and J774 cells stimulated with
LPS (10 ng/mL). Isolated RNA was reverse-transcribed, and
dilution series of cDNA ranging from 1 pg to 10 ng were
subjected to real-time PCR. The obtained threshold cycle
values were plotted against the dilution factor to create a
standard curve. Relative mRNA levels in test samples were
then calculated from the standard curve.
2.8. Downregulation of DUSP1 by siRNA. Human DUSP1
siRNA 1 (Cat. no. J-003484-09-0005) and human DUSP1
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Table 1: Primer and probe sequences for quantitative RT-PCR.
Gene Oligonucleotide Sequence Conc. (nM)
Human GAPDH
Forward primer TCCTACCACCAGCAACCCTGCCA 300
Reverse primer GCAACAATATCCACTTTACCAGAGTTAA 300
Probe CGCCTGGTCACCAGGGCTGC 150
Human iNOS
Forward primer GCAGGTCGACTATTTCTTTCA 300
Reverse primer TCCTCCTCCGCCTCGTAAGGA 300
Probe TCAAGAGCCAGAAGCGCTATCACGAAGATA 150
Mouse GAPDH
Forward primer GCATGGCCTTCCGTGTTC 300
Reverse primer GATGTCATCATACTTGGCAGGTTT 300
Probe TCGTGGATCTGACGTGCCGCC 150
Mouse iNOS
Forward primer CCTGGTACGGGCATTGCT 300
Reverse primer GCTCATGCGGCCTCCTT 300
Probe CAGCAGCGGCTCCATGACTCCC 150
Mouse DUSP1
Forward primer CTCCTGGTTCAACGAGGCTATT 300
Reverse primer TGCCGGCCTGGCAAT 300
Probe CCATCAAGGATGCTGGAGGGAGAGTGTT 150
siRNA 2 (Cat. no. J-003484-10-0005) were purchased from
Dharmacon (Dharmacon, Lafayette, Colo, USA). Lamin
A/C siRNA (Cat. no. 1022050,) and nontargeting control
siRNA (Cat. no. 1022076) were purchased from QIAGEN
(QIAGEN, Valencia, Calif, USA).Mouse DUSP1 was silenced
using ON-TARGET SMART pool (Dharmacon, Cat. no.
L-040753-00-0005). siCONTROL nontargeting siRNA #1
(Dharmacon, Cat. no. D-001210-01) was used as a negative
control siRNA in J774 cells.
A549 cells were transfected with siRNA using HiPerFect
transfection Reagent (QIAGEN) according to the manu-
facturer’s instructions. Briefly, cells (1.25 × 105 cells/well)
were seeded on a 24-well plate in 500 μL of medium with
5% FBS without antibiotics. For one well, 3 μL of siRNA
stock solution (2 μM) was mixed with 1.5 μL of transfection
reagent in final volume of 100 μL of medium, incubated for
5 min in room temperature, and applied over the cells. Cells
were further incubated for 48 h. Fresh culture medium was
changed and cytokines were added into the culture medium.
Cells were further incubated for the time indicated, and gene
expression was analyzed.
J774 cells were transfected with siRNA using Dharma-
FECT 4 transfection reagent (Dharmacon, Lafayette, Colo,
USA) according to the manufacturer’s instructions. Briefly,
cells (1 × 105 cells/well) were seeded on a 24-well plate in
500 μL of medium with 5% FBS without antibiotics and
incubated overnight. For one well, the final transfection
medium applied to the cells contained 25 μL of siRNA stock
solution (2 μM) mixed with 1 μL of transfection reagent
in final volume of 500 μL of medium. Cells were further
incubated for 48 h. Fresh culture medium was changed, and
LPS was added into the culture medium. Cells were further
incubated for the time indicated, and gene expression was
analyzed.
Transfection eﬃcacy was monitored with green fluores-
cent siRNA oligos (siGLO green transfection indicator, Cat.
no. D-001630-01, Dharmacon, Lafayette, Colo, USA) using
Nikon Eclipse TS100 microscope (Nikon, Tokyo, Japan).
Approximately 90% of the cells emitted green fluorescence
signal when transfected with siGLO and HiPerFect (A549
cells) or siGLO and DharmaFECT 4 (J774 cells). Less than
5% of the cells emitted signal when cells were incubated
siGLO oligos without transfection reagent.
2.9. Statistics. Results are expressed as the mean± S.E.M.
When appropriate, one-way ANOVA with Dunnett’s or
Bonferroni’s post test was performed using GraphPad InStat
version 3.05 for Windows 95/NT (GraphPad Software, San
Diego, Calif, USA). Diﬀerences were considered significant
at ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001.
3. Results
3.1. p38 MAPK Inhibitors SB202190 and BIRB 796 Down-
regulated iNOS Expression and NO Production in Response
to Inflammatory Stimuli in A549 Cells and J774 Cells.
A549 pulmonary epithelial cells and J774 macrophages were
stimulated with a cytokine mixture (TNF, IFNγ, and IL-
1β; 10 ng/mL each) and LPS (10 ng/mL), respectively, for
the time indicated. Cells were then harvested for protein
extraction, and the phosphorylation of p38 MAPK was
detected by Western blot. p38 MAPK phosphorylation was
increased in response to stimulation at time point of 30min,
and it was returned to the basal level in 1 h (Figure 1(a)).
p38 MAPK inhibitors SB202190 and BIRB 796 have been
reported to eﬀectively inhibit p38MAPK at 1 μMand 100 nM
concentrations, respectively [50]. To confirm the inhibiting
eﬀect of SB202190 and BIRB 796 on p38 MAPK activity
in the current experimental condition, their eﬀect on the
phosphorylation of p38 MAPK substrate MK2 (47 kDa)
was investigated in A549 cells and J774 cells. Cells were
preincubated with p38 MAPK inhibitors SB202190 or BIRB
796 for 30min and stimulated with the cytokine mixture or
LPS for 30min. The phosphorylation of MK2 was detected
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Figure 1: Phosphorylation of p38 MAPK and its substrate MK2 in response to stimulation with cytokine mixture or LPS in A549 and J774
cells. (a) A549 and J774 cells were stimulated with the cytokine mixture (CM: TNF, IFNγ, and IL-1β; 10 ng/mL each) or LPS (10 ng/mL),
respectively for the time indicated. Cells were then harvested for protein extraction, and phosphorylation of p38 MAPK was detected by
Western blot. The gel is a representative of six separate experiments with similar results. Chemiluminescent signal was quantified, and
phosphorylated p38 MAPK was normalized against total p38 MAPK. Phosphorylation levels are expressed in arbitrary units, unstimulated
cells set as 1, and the other values are related to that. Results are expressed as mean± S.E.M.; n = 6. One-way ANOVA with Dunnett’s
posttest was performed, and statistical significance was indicated with ∗∗P < .01 compared with unstimulated cells. ((b) and (c)) The eﬀect
of SB202190 and BIRB 796 on the phosphorylation of MK2 in response to cytokine mixture in A549 and J774 cells. Cells were preincubated
with SB202190 (1 μM) or BIRB 796 (100 nM) for 30 min and stimulated with cytokine mixture (A549 cells) or LPS (J774 cells) for 30min,
and the phosphorylation of MK2 was detected by Western blot. The gels are representatives of six separate experiments with similar results.
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Figure 2: Expression of iNOS mRNA over time and eﬀects of SB202190 and BIRB 796 on the expression of iNOS mRNA in response
to cytokine mixture in A549 cells. (a) Cells were stimulated with cytokine mixture (CM: TNF, IFNγ, and IL-1β; 10 ng/mL each) for the
time indicated, and total RNA was extracted. The expression of iNOS mRNA was determined by quantitative real-time RT-PCR, and
mRNA expression was normalized against GAPDH mRNA. Unstimulated cells (0 h) were set as 1, and other values were related to that.
Results are expressed as mean± S.E.M., n = 3. One-way ANOVA with Dunnett’s posttest was performed, and statistical significance is
indicated with ∗∗P < .01 as compared to unstimulated cells. (b) Cells were preincubated with SB202190 (1 μM) or BIRB 796 (100 nM) for
30min, stimulated with cytokine mixture for 6 h, and harvested for total RNA extraction. The expression of iNOSmRNAwas determined by
quantitative real-time RT-PCR, and mRNA expression was normalized against GAPDH mRNA. Results are expressed as a percentage of CM,
mean± S.E.M., n = 6. One-way ANOVA with Bonferroni’s posttest was performed, and statistical significance is indicated with ∗∗∗P < .001
as compared to cells treated with CM.
by Western blot. SB202190 and BIRB 796 inhibited MK2
phosphorylation at concentrations of 1 μM and 100 nM,
respectively (Figures 1(b) and 1(c)). These results confirmed
that SB202190 and BIRB 796, at concentrations used,
inhibited p38 MAPK function.
The expression of iNOS mRNA over time was investi-
gated in A549 cells. Cells were stimulated with the cytokine
mixture for 0–6 h, and iNOS mRNA levels were measured.
iNOS mRNA expression was increased in response to the
stimulation with cytokine mixture up to 6 h (Figure 2(a)).
The eﬀect of p38 MAPK inhibitors on iNOS mRNA
expression was investigated. Cells were preincubated with
SB202190 (1 μM) and BIRB 796 (100 nM) for 30min and
stimulated for 6 h. SB202190 and BIRB 796 inhibited the
expression of iNOS mRNA in A549 cells (Figure 2(b)).
The eﬀects of p38 MAPK inhibitors SB202190 and BIRB
796 on iNOS protein expression and NO production were
investigated. Cells were preincubated with SB202190 or BIRB
796 for 30min and stimulated with the cytokine mixture
(A549 cells) or LPS (J774 cells) for 24 h. Supernatants
were collected and total cellular proteins were extracted
for determination of nitrite production (a stable metabolite
of NO in aqueous solution) and iNOS protein expression,
respectively. Unstimulated cells did not express detectable
levels of iNOS or produce NO, and pretreatment with
SB202190 or BIRB 796 alone did not induce iNOS expression
or NO production. Stimulation with the cytokine mixture or
LPS induced iNOS protein expression and NO production,
and SB202190 and BIRB 796 inhibited iNOS expression
and NO production in A549 cells (Figure 3) and J774 cells
(Figure 4) in a dose-dependent manner.
3.2. DUSP1 Negatively Regulated the Phosphorylation of
p38 MAPK. The expression of DUSP1 was investigated in
A549 and J774 cells. A549 and J774 cells were stimulated
with the cytokine mixture (TNF, IFNγ, and IL-1β) and
LPS, respectively, and cells were then harvested for total
RNA or protein extraction at the time points indicated.
Unstimulated cells showed low-level basal DUSP1 protein
(40 kDa) expression. DUSP1 mRNA and protein expression
was enhanced by the cytokine mixture (A549 cells) or LPS
(J774 cells). The maximal mRNA and protein expression
was observed at 1 h after stimulation (Figure 5). DUSP1
mRNA expression was returned to basal level in 2 h in
both cell types. DUSP1 protein expression was reduced
near the basal level at 2 h and 3 h in A549 and J774 cells,
respectively (Figure 5). In DUSP1 Western blots in A549
cells, an immunoreactive band of higher molecular weight
was observed. The manufacturer’s data sheet suggests this to
be DUSP4. The immunoreactive band of higher molecular
weight was not reduced by DUSP1 siRNA indicating that it is
a molecule diﬀerent from DUSP1 (Figure 6(a)).
To investigate the eﬀect of DUSP1 on the phosphoryla-
tion of p38 MAPK, we used siRNA to downregulate DUSP1
expression. In A549 cells transfected with two DUSP1-
specific siRNAs, the protein and mRNA levels of DUSP1
were reduced as compared to the cells transfected with a
nontargeting control siRNA showing that siRNA eﬀectively
downregulated DUSP1 (Figure 6(a)). The downregulation
of DUSP1 by siRNA resulted in an increased p38 MAPK
phosphorylation in response to stimulation at 1 h in A549
cells (Figure 6(a)). Lamin A/C siRNA, used as a positive
control, downregulated lamin A/C mRNA by approximately
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Figure 3: The eﬀect of p38 MAPK inhibitors BIRB 796 and SB202190 on iNOS expression and NO production in response to cytokine
mixture in A549 cells. A549 cells were preincubated with increasing concentrations of (a) BIRB 796 or (b) SB202190 for 30 min and
stimulated with a cytokine mixture (CM: TNF, IFNγ, and IL-1β; 10 ng/mL each) for 24 h. iNOS expression was detected by Western blot.
The gels are representatives of six separate experiments with similar results. Chemiluminescent signal was quantified, and iNOS (iNOS)
expression was normalized to actin. NO production was measured as nitrite accumulated in the culture medium by Griess reaction. The
results are expressed as mean± S.E.M., n = 6. One-way ANOVA with Dunnett’s posttest was performed, and statistical significance is
indicated with ∗P < .05 and ∗∗P < .01 compared to cells treated with CM.
67% (n = 3, data not shown), but it did not aﬀect DUSP1
expression or p38 MAPK phosphorylation in A549 cells
(Figure 6(a)). The eﬀect of DUSP1 siRNA on DUSP1
expression and p38 MAPK phosphorylation was investigated
in J774 cells also. DUSP1 siRNA inhibited DUSP1 mRNA
and protein expression and enhanced p38 MAPK phospho-
rylation in J774 cells (Figure 6(b)). These results show that
DUSP1 catalyzed the dephosphorylation of p38 MAPK and
thereby inactivated p38 MAPK in A549 and J774 cells.
3.3. DUSP1 Negatively Regulated iNOS Expression and NO
Production. The eﬀect of down-regulation of DUSP1 on
iNOS expression and NO production in response to the
cytokine mixture (TNF, IFNγ, and IL-1β; A549 cells) or LPS
(J774 cells) was investigated. A549 cells were transfected with
two DUSP1-specific siRNA. Cells were then stimulated with
the cytokine mixture for 6 h (iNOS mRNA analysis) and 24 h
(iNOS protein analysis and NO production). Silencing of
DUSP1 by siRNA resulted in increased iNOS mRNA and
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Figure 4: The eﬀect of p38 MAPK inhibitor BIRB 796 on mouse iNOS protein expression and NO production in response to LPS in J774
cells. J774 cells were preincubated with increasing concentrations of BIRB 796 for 30min and stimulated with LPS (10 ng/mL) for 24 h. iNOS
protein expression was detected with Western blot. Chemiluminescent signal was quantified, and iNOS expression was normalized to lamin.
The gels are representatives of six separate experiments with similar results. Results are expressed as a percentage of LPS, mean± S.E.M.,
n = 6. NO production was measured as nitrite accumulated in the culture medium by Griess reaction, and the results are expressed as
mean± S.E.M., n = 6. One-way ANOVA with Dunnett’s posttest was performed, and statistical significance is indicated with ∗∗P < .01
compared to LPS-treated cells.
protein expression and NO production in A549 cells (Figures
7(a) and 7(b)). Human iNOS mRNA expression induced
by cytokine mixture in untransfected cells was comparable
to that seen in transfected cells (Figure 7(a)). Untransfected
cells expressed human iNOS protein at somewhat higher
level and produced slightly more NO as compared to the
transfected cells (Figure 7(b)). Similarly, down-regulation
of DUSP1 by siRNA increased iNOS protein expression in
J774 cells (Figure 7(c)). In A549 cells, Lamin A/C-specific
siRNA did not aﬀect iNOS expression or NO production
(Figures 7(a) and 7(b)) although it downregulated lamin
A/C expression by about 70%. This strongly suggests that
the increased iNOS expression and NO production in A549
cells caused by DUSP1-specific siRNA (Figures 7(a) and
7(b)) were due to the down-regulation of DUSP1 and not to
nonspecific eﬀects of siRNA, or general activation of RNA-
induced silencing complex (RISC) pathway.
To further confirm the eﬀect of DUSP1 on iNOS
expression, the induction of iNOS expression by LPS was
investigated in bone marrow macrophages (BMMs) from
DUSP1(−/−) and wild-type mice. BMMs were stimulated
with LPS (10 ng/mL) for 24 h. Cells were harvested for
protein extraction, and iNOS expression was analyzed
by Western blot. Unstimulated cells from wild-type and
DUSP1(−/−) mice did not express detectable amounts of
iNOS. LPS enhanced iNOS expression in BMMs, and LPS-
induced iNOS expression was markedly enhanced in BMMs
isolated from DUSP1(−/−) mice as compared to cells from
wild-type mice (Figure 8).
4. Discussion
In the present study, we investigated the eﬀect of DUSP1 on
the expression of iNOS and production of NO in response
to stimulation with cytokines (TNF, IFNγ, and IL-1β) in
human A549 lung epithelial cells and with LPS in murine
J774 macrophages and primary mouse BMMs. The main
finding of this study was that DUSP1 negatively regulates
iNOS expression and NO production by inhibiting the p38
MAPK phosphorylation both in mouse and human cells.
This is the first study showing that DUSP1 regulates iNOS
expression in human cells.
Structurally distinct p38 MAPK inhibitors SB202190 and
BIRB 796 have been reported to inhibit p38 MAPK at
concentration range of 100 nM to 1 μM in kinase assays [50].
We have previously reported that SB202190 and BIRB 796
inhibit phosphorylation of MK2 (a p38 MAPK substrate)
in a dose-dependent manner with maximal inhibition at
1 μM and 100 nM concentrations, respectively [47]. In the
present study, SB202190 and BIRB 796 inhibited MK2 phos-
phorylation at these concentrations showing that both these
inhibitors eﬀectively inhibited p38 MAPK function in A549
and J774 cells. iNOS mRNA expression was reduced by both
p38 MAPK inhibitors at these concentrations in A549 cells.
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Figure 5: Expression of DUSP1 in response to cytokine mixture or LPS in A549 and J774 cells. Cells were stimulated with (a) cytokines
(CM: TNF, IFNγ, and IL-1β; 10 ng/mL each) or (b) LPS (10 ng/mL) for the time indicated, and DUSP1 mRNA and protein expression was
determined by quantitative real-time RT-PCR and Western blot, respectively. DUSP1 mRNA expression was normalized against GAPDH
mRNA. In Western blots, chemiluminescent signal was quantified and DUSP1 protein expression was normalized against actin. The gels are
representatives of six separate experiments with similar results. DUSP1 protein and mRNA levels are expressed in arbitrary units, DUSP1
expression in unstimulated cells (0 h) is set as 1, and the other values are related to that (mean± S.E.M.; n = 6). One-way ANOVA with
Dunnett’s posttest was performed, and statistical significance is indicated with ∗P < .05 and ∗∗P < .01 compared with unstimulated cells.
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Figure 6: The eﬀect of DUSP1 siRNA on DUSP1 expression and p38 MAPK phosphorylation in A549 and J774 cells. (a) A549 cells
were transfected with DUSP1-specific siRNA 1 or 2 (DUSP1 siRNA 1 or 2), nontargeting control siRNA (control siRNA), or Lamin A/C-
specific siRNA (Lamin A/C siRNA). (b) J774 cells were transfected with DUSP1-specific siRNA (siMKP-1) or nontargeting siRNA (siNEG).
Cells were stimulated with cytokines (CM: TNF, IFNγ, and IL-1β; 10 ng/mL each) or LPS (10 ng/mL) for 1 h. DUSP1 mRNA expression
was determined by quantitative real-time RT-PCR and normalized against GAPDH mRNA. DUSP1 protein expression and p38 MAPK
phosphorylation were determined by Western blot. Chemiluminescent signal was quantified and DUSP1 expression was normalized against
actin, and phosphorylated p38MAPKwas normalized against total p38MAPK. Results are expressed as a percentage of CM or LPS. One-way
ANOVA with Bonferroni’s posttest was performed, and statistical significance is indicated with ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001, n = 6,
except for DUSP1 mRNA in J774 cells, n = 3.
Also, iNOS protein expression and NO production were
reduced by SB202190 and BIRB 796 in a dose-dependent
manner in both A549 and J774 cells. iNOS expression has
been reported to be inhibited by a p38 MAPK inhibitor
SB203580, a compound structurally related to SB202190, at
corresponding concentrations in human cells [13], and by
SB203580 and SB202190 in J774 cells [35].
DUSPs are protein phosphatases capable to dephospho-
rylate tyrosine and threonine/serine residues and, hence,
regulate the activity of their target proteins. A subgroup
of DUSPs target MAPKs and dephosphorylate tyrosine and
threonine residues in MAPKs. Currently, at least ten MAPK-
associated DUSPs have been identified and they diﬀer from
each other by substrate specificity, tissue distribution, cellular
localization, and expressional pattern [40, 44]. DUSP1 is a
nuclear phosphatase inducible by LPS and cytokines, and
it has substrate specificity towards p38 MAPK and JNK.
DUSP1 has been shown to regulate the phosphorylation
of p38 MAPK and JNK in primary mouse macrophages
[42, 43, 51] and endothelial cells [52]. We have recently
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Figure 7: The eﬀect of DUSP1 siRNA on iNOS mRNA and protein expression and NO production in A549 and J774 cells. A549 cells
were transfected with DUSP1-specific siRNA 1 or 2 (DUSP1 siRNA 1 or 2), nontargeting control siRNA (control siRNA) or Lamin A/C-
specific siRNA (Lamin A/C siRNA), and untransfected cells were used as controls. (a) Cells were stimulated with the cytokine mixture
(CM: TNF, IFNγ, and IL-1β; 10 ng/mL each) for 6 h, and iNOS mRNA was determined with quantitative real-time PCR and normalized
against GAPDH mRNA. (b) Cells were stimulated with CM for 24 h, and iNOS protein expression was detected by Western blot and NO
production as nitrite by Griess reaction. (c) J774 cells were transfected either with DUSP1-specific siRNA (siDUSP1) or nontargeting siRNA
(siNEG). Cells were stimulated with LPS (10 ng/mL) for 24 h, and iNOS protein expression was detected by Western blot. In Western blots,
chemiluminescent signal was quantified and iNOS expression was normalized against actin. Results are expressed as related to cells treated
with CMor LPS. One-way ANOVAwith Bonferroni’s posttest was performed, and statistical significance is indicated with ∗P < .05; ∗∗P < .01
and ∗∗∗P < .001, n = 6.
reported that DUSP1 regulates the phosphorylation of both
p38 MAPK and JNK in A549 human pulmonary epithelial
cells [47] and p38 MAPK in chondrocytes [48]. In the
present study, stimulation with cytokines or LPS enhanced
the expression of DUSP1 in A549 and J774 cells. Transfection
of DUSP1-specific siRNA decreased DUSP1 protein and
mRNA expression and resulted in enhanced p38 MAPK
phosphorylation, iNOS expression, and NO production in
A549 cells. This is the first report showing that DUSP1
regulates human iNOS expression.
Down-regulation of DUSP1 by siRNA increased iNOS
expression also in murine macrophages. Accordingly, LPS-
induced iNOS expression was enhanced in BMMs isolated
from DUSP1-deficient mice, which confirmed our results
with cells in which DUSP1 had been silenced with siRNA.
These results are also in line with the previous reports
showing that iNOS expression is increased in DUSP1-
deficient mice in response to low-dose LPS administration
or septicemia due to Gram-positive bacteria in vivo [45, 46].
Interestingly, E. coli infection in DUSP1-deficient mice was
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percentage of LPS, mean± S.E.M. (n = 3). One-way ANOVA with
Bonferroni’s posttest was performed, and statistical significance is
indicated with ∗P < .05 and ∗∗∗P < .001.
reported to result in reduced serum nitrate levels and lower
iNOS expression in liver as compared to wild-type mice
[53]. These conflicting findings may reflect the diﬀerences
in innate immune response to purified cell wall component
(LPS) of Gram-negative bacteria and viable bacteria.
Translation of the results describing the mechanisms of
mouse iNOS expression to that of human is not always
straightforward. The size of the iNOS promoter diﬀers
greatly between mouse (∼1.5 kb) and human (up to 16 kb).
LPS and IFNγ induce mouse iNOS promoter activity 50–
100-fold [5]. Human iNOS promoter shows low basal
activity in the absence of measurable mRNA [19, 54].
Cytokine stimulation increases human iNOS promoter activ-
ity only approximately 7-to-10 fold, while mRNA expression
increases more than 100-fold [8, 19]. This demonstrates the
diﬀerences in transcriptional but also in posttranscriptional
regulation of iNOS expression between mouse and human
cells. From a therapeutic point of view, the mechanisms
regulating iNOS expression ought to be applicable for
human iNOS expression. In this study, we demonstrated
the negative regulation of human iNOS expression by
DUSP1, which has not previously been reported. Also,
DUSP1 regulated mouse iNOS expression. According to our
results, p38 MAPK/DUSP1 pathway seems to be a conserved
signaling/regulatory mechanism for iNOS expression across
species despite the considerable other diﬀerences in the reg-
ulation of iNOS expression between mouse and human. p38
MAPK/DUSP1 pathway may regulate iNOS expression both
at transcriptional and posttranscriptional levels. Human
iNOS has been shown to be regulated by p38 MAPK by a
mechanism dependent on the interaction between human
iNOS mRNA 3′ untranslated region and tristetraprolin,
an mRNA-binding protein. p38 MAPK positively regulates
tristetraprolin, which stabilizes iNOS mRNA and leads to
increased iNOS expression [13]. In addition, human and
rodent iNOS promoter activity has also been reported to be
regulated by p38 MAPK [11, 55, 56].
Therapeutic approaches targeted to enhance DUSP1
expression or its function may provide a novel mechanism
for anti-inflammatory treatment. Glucocorticoids enhance
DUSP1 expression, and some of the anti-inflammatory
eﬀects of glucocorticoids, such as the inhibition of cytokine
and chemokine expression, are mediated by DUSP1 [57, 58].
In alveolar macrophages from patients with glucocorticoid-
resistant asthma, the expression of DUSP1 in response to
glucocorticoids was reported to be reduced and, correspond-
ingly, p38 MAPK phosphorylation was increased [59]. Also,
disease-modifying antirheumatic drug aurothiomalate was
recently found to enhance DUSP1 expression in chondro-
cytes and cartilage, and DUSP1 mediated its inhibitory eﬀect
on COX-2, IL-6, and matrix metalloproteinase 3 expression
[48]. Interestingly, DUSP4, anotherMAPK-associatedDUSP,
has been reported to regulate inflammatory response via
ERK and DUSP1. DUSP4-deficient mice were protected
from the excessive inflammatory response during septic
infection. These animals showed increased ERK phospho-
rylation due to DUSP4 deficiency. Increased ERK activity
resulted in enhanced DUSP1 expression and, in turn,
reduced TNF and IL-6 production by macrophages [60].
In addition to inflammatory conditions, increased iNOS-
derived NO production has been shown to be present
in various solid tumors. Myeloid-derived suppressor cells
(MDSCs) are a group of myeloid progenitor cells, immature
macrophages, granulocytes, and dendritic cells capable of
suppressing functions of T cells. In malignancies, they infil-
trate in solid tumors and promote tumor growth. Tumor-
associated monocytic MDSCs express iNOS at high level.
iNOS-derived NO by MDSCs targets tumor infiltrating T
cells and suppresses their functions by inhibiting T cell recep-
tor signaling and Jak/STAT pathway activation and inducing
T cell apoptosis. NO production is one of the central
mechanisms by which MDSCs promote tumor growth [61].
IL-6 and granulocyte/monocyte colony-stimulating factor
(GM-CSF) have been reported to induce the diﬀerentia-
tion of MDSCs from peripheral blood mononuclear cells
[62]. Interestingly, DUSP1 suppresses IL-6 and GM-CSF,
expression [41, 47, 63]. DUSP1 may limit the diﬀerentiation
and functions on MDSCs by suppressing the expression of
IL-6, GM-CSF and iNOS. DUSP1 has been shown to be
upregulated in early phases of epithelial carcinogenesis in
bladder, colon, and prostate cancers with progressive loss on
expression with higher histological grades and in metastasis
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[64]. In lung cancer, DUSP1 predicted improved survival
[65]. In vitro, DUSP1 overexpression induced apoptosis at
colon cancer cells [66]. These findings imply that DUSP1
may have antitumor activity. However, the antitumor eﬀects
of DUSP1may well be related to the cancer type and the stage
of the disease. It is noteworthy that DUSP1 has been recently
linked to the depressive behavior in animal experiments [67],
and if this appears to be the case also in humans, it may
limit the therapeutic potential of DUSP1 in inflammatory
and other conditions.
5. Conclusions
In conclusion, our results show that DUSP1 negatively
regulated iNOS expression and NO production induced by
inflammatory stimuli by inhibiting p38 MAPK phosphory-
lation in murine and human cells. This study extends our
understanding on the role of DUSP1 in inflammation and on
the mechanisms that regulate iNOS expression especially in
human cells. This may give new insights in the development
of novel drug treatments for diseases complicated with
increased iNOS-mediated NO production.
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